ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2015
PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Molecular imaging tracers targeting c-MET: a systematic review of preclinical evidence and clinical translation.European journal of nuclear medicine and molecular imaging · 2026Review
- Fully automated radiolabeling of [EJNMMI radiopharmacy and chemistry · 2023Article
- Recent progress in the imaging of c-Met aberrant cancers with positron emission tomography.Medicinal research reviews · 2022Review
- SOX8 promotes cetuximab resistance via HGF/MET bypass pathway activation in colorectal cancer.Cancer chemotherapy and pharmacology · 2022Article
- Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.Pharmaceuticals (Basel, Switzerland) · 2021Review
- A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.Theranostics · 2021Review
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging.Frontiers in immunology · 2020Review
- The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches.Nature reviews. Clinical oncology · 2019Review
- PET Imaging of Receptor Tyrosine Kinases in Cancer.Molecular cancer therapeutics · 2018Review
- Imaging c-Met expression using 18F-labeled binding peptide in human cancer xenografts.PloS one · 2018Article
- Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review.EJNMMI research · 2017Review
- Article
- Highlights lecture EANM 2015: the search for nuclear medicine's superheroes.European journal of nuclear medicine and molecular imaging · 2016Article
- Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Article
- Optical Imaging of Mesenchymal Epithelial Transition Factor (MET) for Enhanced Detection and Characterization of Primary and Metastatic Hepatic Tumors.Theranostics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledThe hepatocyte growth factor (HGF) and its receptor, c-Met, are actively involved in tumor progression and metastasis and are closely associated with a poor prognostic outcome for cancer patients. Thus, the development of PET agents that can assess c-Met expression would be extremely useful for diagnosing cancer and subsequently monitoring response to c-Met-targeted therapies. Here, we report the characterization of recombinant human HGF (rh-HGF) as a PET tracer for detection of c-Met expression in vivo.
methodsrh-HGF was expressed in human embryonic kidney 293 cells and purified by nickel-nitrilotriacetic acid affinity chromatography. The concentrated rh-HGF was conjugated to 2-S-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid and labeled with (64)Cu. c-Met binding evaluation by flow cytometry was performed on both U87MG and MDA-MB-231 cell lines, which have a high level and a low level, respectively, of c-Met. PET imaging and biodistribution studies were performed on nude mice bearing U87MG and MDA-MB-231 xenografted tumors.
resultsThe rh-HGF expression yield was 150-200 μg of protein per 5 × 10(6) cells after a 48-h transfection, with purity of approximately 85%-90%. Flow cytometry examination confirmed that rh-HGF had a strong and specific capacity to bind to c-Met. After (64)Cu labeling, PET imaging revealed specific and prominent uptake of (64)Cu-NOTA-rh-HGF in c-Met-positive U87MG tumors (percentage injected dose per gram, 6.8 ± 1.8 at 9 h after injection) and significantly lower uptake in c-Met-negative MDA-MB-231 tumors (percentage injected dose per gram, 1.8 ± 0.6 at 9 h after injection). The fact that sonication-denatured rh-HGF had significantly lower uptake in U87MG tumors, along with histology analysis, confirmed the c-Met specificity of (64)Cu-NOTA-rh-HGF.
conclusionThis study provided initial evidence that (64)Cu-NOTA-rh-HGF visualizes c-Met expression in vivo, an application that may prove useful for c-Met-targeted cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.